OBJECTIVE: To test if estrogen promotes carcinogenesis in vitro and in a genetic mouse model of ovarian cancer and whether its effects can be inhibited by a novel selective estrogen receptor modulator (SERM), bazedoxifene. METHODS: Bazedoxifene was synthesized and it was confirmed that the drug abrogated the uterine stimulatory effect of 17β-estradiol in mice. To determine if hormones alter tumorigenesis in vivo LSL-K-ras(G12D/+)Pten(loxP/loxP) mice were treated with vehicle control, 17β-estradiol or bazedoxifene. Hormone receptor status of a cell line established from LSL-K-ras(G12D/+)Pten(loxP/loxP) mouse ovarian tumors was characterized using Western blotting and immunohistochemistry. The cell line was treated with hormones and invasion assays were performed using Boyden chambers and proliferation was assessed using MTT assays. RESULTS: In vitro 17β-estradiol increased both the invasion and proliferation of ovarian cancer cells and bazedoxifene reversed these effects. However, in the genetic mouse model neither treatment with 17β-estradiol nor bazedoxifene changed mean tumor burden when compared to treatment with placebo. The mice in all treatment groups had similar tumor incidence, metastatic nodules and ascites. CONCLUSION: While 17β-estradiol increases the invasion and proliferation of ovarian cancer cells, these effects do not translate into increased tumor burden in a genetic mouse model of endometrioid ovarian cancer. Likewise, while the SERM reversed the detrimental effects of estrogen in vitro, there was no change in tumor burden in mice treated with bazedoxifene. These findings demonstrate the complex interplay between hormones and ovarian carcinogenesis.
OBJECTIVE: To test if estrogen promotes carcinogenesis in vitro and in a genetic mouse model of ovarian cancer and whether its effects can be inhibited by a novel selective estrogen receptor modulator (SERM), bazedoxifene. METHODS:Bazedoxifene was synthesized and it was confirmed that the drug abrogated the uterine stimulatory effect of 17β-estradiol in mice. To determine if hormones alter tumorigenesis in vivo LSL-K-ras(G12D/+)Pten(loxP/loxP) mice were treated with vehicle control, 17β-estradiol or bazedoxifene. Hormone receptor status of a cell line established from LSL-K-ras(G12D/+)Pten(loxP/loxP) mouseovarian tumors was characterized using Western blotting and immunohistochemistry. The cell line was treated with hormones and invasion assays were performed using Boyden chambers and proliferation was assessed using MTT assays. RESULTS: In vitro 17β-estradiol increased both the invasion and proliferation of ovarian cancer cells and bazedoxifene reversed these effects. However, in the genetic mouse model neither treatment with 17β-estradiol nor bazedoxifene changed mean tumor burden when compared to treatment with placebo. The mice in all treatment groups had similar tumor incidence, metastatic nodules and ascites. CONCLUSION: While 17β-estradiol increases the invasion and proliferation of ovarian cancer cells, these effects do not translate into increased tumor burden in a genetic mouse model of endometrioid ovarian cancer. Likewise, while the SERM reversed the detrimental effects of estrogen in vitro, there was no change in tumor burden in mice treated with bazedoxifene. These findings demonstrate the complex interplay between hormones and ovarian carcinogenesis.
Authors: C P Miller; M D Collini; B D Tran; H A Harris; Y P Kharode; J T Marzolf; R A Moran; R A Henderson; R H Bender; R J Unwalla; L M Greenberger; J P Yardley; M A Abou-Gharbia; C R Lyttle; B S Komm Journal: J Med Chem Date: 2001-05-24 Impact factor: 7.446
Authors: Marion Zillhardt; Sun-Mi Park; Iris L Romero; Kenjiro Sawada; Anthony Montag; Thomas Krausz; S Diane Yamada; Marcus E Peter; Ernst Lengyel Journal: Clin Cancer Res Date: 2011-05-06 Impact factor: 12.531
Authors: Jean A Hurteau; Mark F Brady; Kathleen M Darcy; William P McGuire; Pamela Edmonds; Michael L Pearl; Iouri Ivanov; Krishnansu S Tewari; Robert S Mannel; Kristine Zanotti; Doris M Benbrook Journal: Gynecol Oncol Date: 2010-09-17 Impact factor: 5.482
Authors: Monique A Spillman; Nicole G Manning; Wendy W Dye; Carol A Sartorius; Miriam D Post; Joshua Chuck Harrell; Britta M Jacobsen; Kathryn B Horwitz Journal: Cancer Res Date: 2010-10-19 Impact factor: 12.701
Authors: Saundra S Buys; Edward Partridge; Amanda Black; Christine C Johnson; Lois Lamerato; Claudine Isaacs; Douglas J Reding; Robert T Greenlee; Lance A Yokochi; Bruce Kessel; E David Crawford; Timothy R Church; Gerald L Andriole; Joel L Weissfeld; Mona N Fouad; David Chia; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Patricia Hartge; Paul F Pinsky; Claire S Zhu; Grant Izmirlian; Barnett S Kramer; Anthony B Miller; Jian-Lun Xu; Philip C Prorok; John K Gohagan; Christine D Berg Journal: JAMA Date: 2011-06-08 Impact factor: 157.335
Authors: Peter C Hart; Tatsuyuki Chiyoda; Xiaojing Liu; Melanie Weigert; Marion Curtis; Chun-Yi Chiang; Rachel Loth; Ricardo Lastra; Stephanie M McGregor; Jason W Locasale; Ernst Lengyel; Iris L Romero Journal: Mol Cancer Res Date: 2019-01-17 Impact factor: 5.852
Authors: Ernst Lengyel; Lacey M Litchfield; Anirban K Mitra; Kristin M Nieman; Abir Mukherjee; Yilin Zhang; Alyssa Johnson; Michael Bradaric; WooSeok Lee; Iris L Romero Journal: Am J Obstet Gynecol Date: 2014-10-19 Impact factor: 8.661
Authors: Lisa K Mullany; Zhilin Liu; Kwong-Kwok Wong; Victoria Deneke; Yi Athena Ren; Alan Herron; JoAnne S Richards Journal: Mol Endocrinol Date: 2013-01-01
Authors: Mohammed Habis; Kristen Wroblewski; Michael Bradaric; Nadia Ismail; S Diane Yamada; Lacey Litchfield; Ernst Lengyel; Iris L Romero Journal: PLoS One Date: 2014-08-13 Impact factor: 3.240
Authors: Lacey M Litchfield; Abir Mukherjee; Mark A Eckert; Alyssa Johnson; Kathryn A Mills; Shawn Pan; Viji Shridhar; Ernst Lengyel; Iris L Romero Journal: Oncotarget Date: 2015-09-15
Authors: Pathum Thilakasiri; Jennifer Huynh; Ashleigh R Poh; Chin Wee Tan; Tracy L Nero; Kelly Tran; Adam C Parslow; Shoukat Afshar-Sterle; David Baloyan; Natalie J Hannan; Michael Buchert; Andrew Mark Scott; Michael Dw Griffin; Frederic Hollande; Michael W Parker; Tracy L Putoczki; Matthias Ernst; Ashwini L Chand Journal: EMBO Mol Med Date: 2019-04 Impact factor: 12.137